67th American Society of Hematology Annual Meeting and Exposition (ASH 2025)

Single-agent pirtobrutinib significantly improved progression-free survival (PFS) vs bendamustine plus rituximab (BR) for patients with treatment-naïve chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL), according to the first results from the phase III BRUIN CLL-313 trial.

Findings from the phase III NCRI* FLAIR** trial demonstrate the benefit of MRD***-guided ibrutinib + venetoclax (I+V) in chronic lymphocytic leukaemia (CLL) patients with gene aberrations compared with ibrutinib and fludarabine, cyclophosphamide, and rituximab (FCR).

Combination treatment with the CD20×CD3 bispecific antibody odronextamab and chemotherapy is generally safe among previously untreated diffuse large B cell lymphoma (DLBCL) patients, without new safety signals, as shown by the results from part 1 of the phase III Olympia-3 study.

A retrospective study spanning 25 years has shown that intravenous (IV) iron therapy in hospitalized patients with iron-deficiency anaemia and acute infections is associated with a lower risk of death.

The addition of low-dose aspirin to warfarin appears to increase the risk of major bleeding in patients with antiphospholipid syndrome (APS) but falls short in reducing all-cause mortality, according to a study presented at ASH 2025. Likewise, the rates of ischemic stroke and acute myocardial infarction are also higher among aspirin users.

A study from Canada demonstrates the burden of severe iron deficiency anaemia (IDA) among healthy children in the context of ongoing bottle feeding and excessive cow’s milk intake.